Recursion Pharmaceuticals Inc Cl A (RXRX) Stock Price, Quote & News

Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4...

Industry: Biotechnology

Sector: Healthcare

Phone: 385 269 0203

Fax: 801 821 2872

Website: www.recursion.com

Address:

41 South Rio Grande Street, Salt Lake City, United States

aoab Feb. 23 at 9:14 PM

$RXRX self driving labs? Sounds like we should all hold for a while

0 · Reply

bighoss1188 Feb. 23 at 9:11 PM

$RXRX per most recent 13Fs this boy is ~90% insider+institution owned, up about 10%. All of them are in on average costs at least well above x2 current levels. Does that sound like a scamcoin to you? Do you wake up and think ”hmmm… the house always loses!”

0 · Reply

swwsj Feb. 23 at 9:07 PM

$RXRX looks like good up side volume before the close today. That’s short covering. A good sign!

0 · Reply

Zio_Fauss Feb. 23 at 9:01 PM

$RXRX

0 · Reply

Floridaorange Feb. 23 at 7:20 PM

$RXRX great retail accumulation zone.

0 · Reply

Zio_Fauss Feb. 23 at 7:10 PM

$RXRX In 10 minutes, our friend Cathy starts buying size.

0 · Reply

Thekiss320 Feb. 23 at 6:46 PM

$RXRX Not gonna lie, this one tests your patience. But Recursion isn’t some random biotech — they’ve built a real AI-driven discovery platform with serious pharma partnerships behind it. Revenue won’t be linear, and the market wants proof. Fair. But if even a couple programs convert, this price won’t look cheap in hindsight. Volatile? Yes. Broken? I don’t think so.

0 · Reply

Zio_Fauss Feb. 23 at 6:31 PM

$RXRX I don’t see Gibson selling… What’s going on? Is that useless guy waiting for something?

0 · Reply

Searching4truth Feb. 23 at 4:29 PM

$RXRX How did this pig ever get to $40 a share?

0 · Reply

bighoss1188 Feb. 23 at 2:44 PM

$RXRX Any stock that can come back from major bearish news opening a day -15% and end the day green, in the face of a massive short attack (being one of the markets top 10 most shorted), clearly has the Mandate of Heaven. Only fools quarrel with the will of the Gods.

0 · Reply

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Feb 23, 2026, 7:55 AM EST - 9 hours ago

Recursion to Participate in Upcoming Investor Conferences

Feb 18, 2026, 8:30 AM EST - 5 days ago

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Feb 18, 2026, 5:43 AM EST - 5 days ago

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

APLD NVDA

Jan 22, 2026, 2:54 PM EST - 4 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript

Jan 13, 2026, 5:46 PM EST - 5 weeks ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 6, 2026, 7:59 AM EST - 6 weeks ago

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 26, 2025, 1:28 PM EST - 2 months ago

3 Small AI Plays to Buy for 2026

ANET INOD

Dec 18, 2025, 11:38 AM EST - 2 months ago

Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025

Dec 18, 2025, 11:05 AM EST - 2 months ago

What's Happening With RXRX Stock?

Dec 8, 2025, 4:37 PM EST - 2 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Discusses Updated Safety and Efficacy Data from TUPELO Phase I/II Study of REC-4881 in FAP Transcript

Dec 8, 2025, 7:32 AM EST - 2 months ago

Recursion Pharma's AI-powered therapy reduces colon growth in a rare disease trial

Dec 8, 2025, 7:30 AM EST - 2 months ago

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

Dec 5, 2025, 8:19 AM EST - 2 months ago

Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Dec 1, 2025, 8:30 AM EST - 3 months ago

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

Nov 21, 2025, 7:43 PM EST - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 18, 2025, 10:14 AM EST - 3 months ago

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Nov 5, 2025, 8:11 PM EST - 3 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 6:30 AM EST - 3 months ago

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 6:28 AM EST - 3 months ago

Recursion Announces CEO Transition Plan to Drive Next Phase of Growth

Nov 4, 2025, 8:00 AM EST - 3 months ago

Recursion to Participate in Upcoming Investor Conferences

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Oct 22, 2025, 1:42 PM EDT - 4 months ago

Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks

AI APLD ENVX HIMS IBRX PLUG RKT

Oct 8, 2025, 2:51 PM EDT - 4 months ago

What's Going On With Recursion Pharmaceuticals Stock On Wednesday?

Sep 8, 2025, 8:03 PM EDT - 5 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 3, 2025, 6:51 PM EDT - 6 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 5, 2025, 2:44 PM EDT - 7 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 6:30 AM EDT - 7 months ago

Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 29, 2025, 8:00 AM EDT - 7 months ago

Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th

Jul 25, 2025, 1:53 PM EDT - 7 months ago

How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma

NVDA PLTR

Jul 22, 2025, 7:02 AM EDT - 7 months ago

Top 2 Health Care Stocks You May Want To Dump This Quarter

MEDP

Jun 10, 2025, 6:14 AM EDT - 9 months ago

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

Jun 6, 2025, 10:00 AM EDT - 9 months ago

MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy

May 5, 2025, 1:37 PM EDT - 10 months ago

Recursion Pharmaceuticals, Inc. (RXRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 6:00 AM EDT - 10 months ago

Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 4:02 AM EDT - 10 months ago

Recursion Pharmaceuticals: Looking For Entry Around Q1 Earnings

May 4, 2025, 12:45 PM EDT - 10 months ago

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Apr 28, 2025, 8:27 AM EDT - 10 months ago

Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

Apr 22, 2025, 8:34 PM EDT - 10 months ago

Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

Apr 16, 2025, 8:30 AM EDT - 11 months ago

HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

Apr 9, 2025, 8:00 AM EDT - 11 months ago

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Recursion to Participate in Upcoming Investor Conference

Mar 3, 2025, 11:19 AM EST - 1 year ago

Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says

Feb 28, 2025, 1:16 PM EST - 1 year ago

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 6:30 AM EST - 1 year ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Feb 24, 2025, 8:00 AM EST - 1 year ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Feb 18, 2025, 11:00 AM EST - 1 year ago

Altitude Lab Startups Raise $154M in Capital

Feb 13, 2025, 6:05 PM EST - 1 year ago

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Feb 5, 2025, 5:24 PM EST - 1 year ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Jan 7, 2025, 9:15 AM EST - 1 year ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

aoab Feb. 23 at 9:14 PM

$RXRX self driving labs? Sounds like we should all hold for a while

0 · Reply

bighoss1188 Feb. 23 at 9:11 PM

0 · Reply

swwsj Feb. 23 at 9:07 PM

$RXRX looks like good up side volume before the close today. That’s short covering. A good sign!

0 · Reply

Zio_Fauss Feb. 23 at 9:01 PM

$RXRX

0 · Reply

Floridaorange Feb. 23 at 7:20 PM

$RXRX great retail accumulation zone.

0 · Reply

Zio_Fauss Feb. 23 at 7:10 PM

$RXRX In 10 minutes, our friend Cathy starts buying size.

0 · Reply

Thekiss320 Feb. 23 at 6:46 PM

0 · Reply

Zio_Fauss Feb. 23 at 6:31 PM

$RXRX I don’t see Gibson selling… What’s going on? Is that useless guy waiting for something?

0 · Reply

Searching4truth Feb. 23 at 4:29 PM

$RXRX How did this pig ever get to $40 a share?

0 · Reply

bighoss1188 Feb. 23 at 2:44 PM

0 · Reply

Pika_Plays Feb. 23 at 2:17 PM

$RXRX $PYPL $XOM $KTOS ii

0 · Reply

bighoss1188 Feb. 23 at 2:07 PM

$RXRX Them exaggerating/misleadingly writing both the titles of people involved and their role in this talk (not even listed on the talk brief) and the other upcoming talks is a snub by NVDA and is bearish. HOWEVER The fact that NVDA is in fact snubbing them for no reason lends more circumstantial evidence to my theory that Lilly (who just signed a big contract with NVDA to build out similar capability right when they dumped the stock) is actively trying to burn the company down, meaning they see them as a real threat not just a meme, which at 1.5x book value is giggabullish. Using google trends i have seen a whole lot of search terms for more obscure RXRX product lines or people lighting up Indianapolis (Lily HQ) like the North Star.

1 · Reply

bighoss1188 Feb. 23 at 1:56 PM

$RXRX

0 · Reply

Bulltrader988 Feb. 23 at 1:41 PM

$RXRX "..announced today it will be featured in HighRes’ Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development..." 👃👀 https://www.stocktitan.net/news/RXRX/recursion-to-be-featured-in-high-res-lightning-talk-at-nvidia-ie20bgazrc0u.html

1 · Reply

ZacksResearch Feb. 23 at 1:39 PM

5 medical names heading into earnings — ready for upside surprises or bracing for volatility? $IRWD $RXRX $NVAX $VTRS $NTLA are gearing up to report as the Medical sector shows solid sales growth so far, even with a slight profit dip. That combo can set the stage for sharp moves if expectations get reset. Big reactions could be coming. See what’s at stake for these stocks 👉 https://www.zacks.com/stock/news/2873363/whats-in-store-for-these-5-medical-companies-this-earnings-season?cid=sm-stocktwits-2-2873363-teaser-34570&ADID=SYND_STOCKTWITS_TWEET_2_2873363_TEASER_34570

1 · Reply

Tobitski Feb. 23 at 1:32 PM

$RXRX Who could have thought that 😅. Super bullish. Keep your 💎 folks 🍻 🧐 💣

1 · Reply

BigPennyStockAlerts Feb. 23 at 1:07 PM

$RXRX Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

0 · Reply

BreakoutPika Feb. 23 at 1:07 PM

$BBAI $RXRX $RGTI $PL ::

0 · Reply

Spartangio Feb. 23 at 1:05 PM

$RXRX Collaborating

0 · Reply

Spartangio Feb. 23 at 1:04 PM

$RXRX Recursion To Be Featured in HighRes’ Lightning Talk at NVIDIA GTC Nvidia still Working with us “Recursion continues to push the frontier of drug discovery through the power of accelerated computing and AI,” said Rory Kelleher, Senior Director, Global Head of Business Development, Healthcare and Life Sciences at NVIDIA. “This year at GTC, we’re collaborating across the ecosystem to move Physical AI from concept to reality, unlocking a new era of biological insight and therapeutic speed.”

0 · Reply

Bulltrader988 Feb. 23 at 1:02 PM

$RXRX "...TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026 Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026 KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026..." Busy month ahead 👃👀 https://www.stocktitan.net/news/RXRX/recursion-to-participate-in-upcoming-investor-qnkb7vq97kqq.html

0 · Reply

Tobitski Feb. 23 at 11:04 AM

$RXRX 25 ,Will be important 💣

0 · Reply

Market Cap	1.78B
Revenue (ttm)	58.84M
Net Income (ttm)	-463.66M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-788.00%
Debt to Equity Ratio	0.01

Volume	14,371,950
Avg Vol	22,344,449
Day's Range	N/A - N/A
Shares Out	519.84M
Stochastic %K	40%
Beta	0.95
Analysts	Sell
Price Target	$7.00